United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.		
08/849,525	08/29/1997	GHITA LANZENDORFER	435-WCG	435-WCG 3976		
7:	590 11/22/2006		EXAMINER			
Greenblum & Bernstein, P.L.C. 1950 Roland Clarke Place			COTTON, ABIC	COTTON, ABIGAIL MANDA		
Reston, VA 2			ART UNIT	PAPER NUMBER		
•			1617			
			DATE MAILED: 11/22/2006	DATE MAILED: 11/22/2006		

Please find below and/or attached an Office communication concerning this application or proceeding.

Advisory Action Before the Filing of an Appeal Brief

Application No.		Applicant(s)		
0	8/849,525	LANZENDORFER ET AL.		
Examiner		Art Unit		
A	bigail M. Cotton	1617		

	Abigail M. Co	ton	1617	
The MAILING DATE of this communication appe	ears on the cov	er sheet with the	correspondence add	ress
THE REPLY FILED 07 November 2006 FAILS TO PLACE THIS	S APPLICATIO	N IN CONDITION F	OR ALLOWANCE.	
1. The reply was filed after a final rejection, but prior to or or this application, applicant must timely file one of the follow places the application in condition for allowance; (2) a Not a Request for Continued Examination (RCE) in compliant time periods:	n the same day wing replies: (1) otice of Appeal (as filing a Notice of an amendment, af with appeal fee) in	f Appeal. To avoid aba ffidavit, or other evider compliance with 37 C	nce, which FR 41.31; or (3)
a) The period for reply expiresmonths from the mailin	g date of the final	rejection.		
b) The period for reply expires on: (1) the mailing date of this A no event, however, will the statutory period for reply expire I Examiner Note: If box 1 is checked, check either box (a) or TWO MONTHS OF THE FINAL REJECTION. See MPEP 7	Advisory Action, o ater than SIX MO (b). ONLY CHEC	r (2) the date set forth NTHS from the mailir	ng date of the final rejecti	on.
Extensions of time may be obtained under 37 CFR 1.136(a). The date have been filed is the date for purposes of determining the period of ex under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the set forth in (b) above, if checked. Any reply received by the Office late may reduce any earned patent term adjustment. See 37 CFR 1.704(b) NOTICE OF APPEAL	tension and the c shortened statuto r than three mont	orresponding amount ry period for reply orig	of the fee. The appropri	ate extension fee ce action; or (2) as
2. The Notice of Appeal was filed on A brief in comp filing the Notice of Appeal (37 CFR 41.37(a)), or any exte a Notice of Appeal has been filed, any reply must be filed AMENDMENTS	nsion thereof (3	37 CFR 41.37(e)), to	o avoid dismissal of th	
3. The proposed amendment(s) filed after a final rejection, (a) They raise new issues that would require further co (b) They raise the issue of new matter (see NOTE below	nsideration and			ecause
(c) They are not deemed to place the application in be appeal; and/or				the issues for
(d) They present additional claims without canceling a NOTE: (See 37 CFR 1.116 and 41.33(a)).		iumber of imally re	jected claims.	
4. The amendments are not in compliance with 37 CFR 1.10 and 41.35(a)).		d Natice of Non Co	ampliant Amandment	(DTOL 224)
5. Applicant's reply has overcome the following rejection(s)		d Notice of Non-Co	ompliant Amendment	P 10L-324).
Newly proposed or amended claim(s) would be all non-allowable claim(s).		nitted in a separate,	timely filed amendme	nt canceling the
7. For purposes of appeal, the proposed amendment(s): a) how the new or amended claims would be rejected is pro The status of the claim(s) is (or will be) as follows: Claim(s) allowed: Claim(s) objected to: Claim(s) rejected: Claim(s) withdrawn from consideration:			ill be entered and an e	xplanation of
AFFIDAVIT OR OTHER EVIDENCE				
 The affidavit or other evidence filed after a final action, but because applicant failed to provide a showing of good an was not earlier presented. See 37 CFR 1.116(e). 				
9. The affidavit or other evidence filed after the date of filing entered because the affidavit or other evidence failed to of showing a good and sufficient reasons why it is necessar	overcome <u>all</u> rej y and was not e	ections under appe arlier presented. S	eal and/or appellant fai See 37 CFR 41.33(d)(1	ls to provide a
10. The affidavit or other evidence is entered. An explanatio REQUEST FOR RECONSIDERATION/OTHER	n of the status	of the claims after e	entry is below or attach	ed.
 The request for reconsideration has been considered but please see continuation sheet. 			in condition for allowar	ice because:
12. Note the attached Information Disclosure Statement(s).	(PTO/SB/08) Pa	aper No(s)	$\Omega U \wedge$	
13. Other:		.4	Malm	nellan
		.e		

SREENI PADMANABHAN SUPERVISORY PATENT EXAMINER Application/Control Number: 08/849,525

Art Unit: 1617

Continuation sheet (note # 11)

The request for reconsideration has been considered but does not place the application in condition for allowance. In particular, Applicants argue that there is no motivation to combine the teachings of Evans and Suzuki. The Examiner respectfully disagrees. As set forth in the Final Rejection mailed on September 13, 2006, Evans et al. teaches that antioxidants can be applied to skin to control oxidative damage from UVB radiation, such as in sunburn, whereas Suzuki et al. teaches that alpha-glucosyl rutin has antioxidative effects and can be suitably provided in cosmetic compositions. Thus, one of ordinary skill in the art at the time the invention was made would have found it obvious to provide the alpha-glucosyl rutin in the treatment method of Evans et al, with the expectation of providing a suitable antioxidant effective for reducing controlling oxidative damage caused by exposure to UVB radiation.

Applicants also argue that it is not obvious to combine the teachings of Evans et al. and Suzuki et al, with those of Harrison. The Examiner respectfully disagrees. As discussed in the Final Rejection mailed on September 13, 2006, *Harrison's* teaches that excessive amounts of UVB radiation can lead to immunosuppression of skin cells, and thus it is considered that the population of individuals that has been exposed to excessive UVB radiation, such as those having sunburn, are a population that closely overlaps with and/or is the same as those patients in need of treatment or modulation of the immunosuppression of skin cells induced by the UVB radiation. Accordingly, it is

Art Unit: 1617

considered that the skin treatment method of Evans et al. and Suzuki et al, as evidenced by the entry in *Harrison's*, provides treatment or modulation of immunosuppression of skin cells induced by UVB radiation because the method of Evans et al. and Suzuki et al. teaches the treatment of skin, such as sunburned skin, which has been exposed to excessive UVB radiation, and which is thus likely to have immunosuppression of the skin cells.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Abigail M. Cotton whose telephone number is (571) 272-8779. The examiner can normally be reached on 9:30-6:00, M-F.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sreenivasan Padmanabhan can be reached on (571) 272-0629. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 1617

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

AMC